Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2025)

Vivos Therapeutics' Current Deferred Revenue history spans 7 years, with the latest figure at $479000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $479000.0 for Q4 2025, down 46.54% from a year ago — trailing twelve months through Dec 2025 was $479000.0 (down 46.54% YoY), and the annual figure for FY2025 was $479000.0, down 46.54%.
  • Current Deferred Revenue for Q4 2025 was $479000.0 at Vivos Therapeutics, down from $538000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.1 million in Q2 2021 to a low of $479000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $2.4 million (2021), against an average of $2.2 million.
  • The sharpest move saw Current Deferred Revenue skyrocketed 35.14% in 2021, then crashed 79.73% in 2025.
  • Year by year, Current Deferred Revenue stood at $2.4 million in 2021, then grew by 26.64% to $3.0 million in 2022, then decreased by 20.11% to $2.4 million in 2023, then tumbled by 63.08% to $896000.0 in 2024, then plummeted by 46.54% to $479000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $479000.0, $538000.0, and $485000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.